Selenium and Mild Graves' Orbitopathy — What a Randomized Trial Showed

Hashimoto's disease, which we've already covered on this blog in connection with ashwagandha and thyroid supplementation, is autoimmune hypothyroidism — the immune system gradually destroys the gland, hormone production falls, and the patient slows down: gaining weight, feeling cold, tired, and sleepy. Graves' disease is its mirror image. It's also an autoimmune disease, but the antibodies don't destroy the thyroid — instead they overstimulate it, binding to the TSH receptor and forcing the gland to produce excess hormones. The effect is the opposite of Hashimoto's: rapid heart rate, weight loss despite a good appetite, excessive sweating, hand tremor, anxiety, and insomnia.

This distinction matters in practice, because the two diseases are often confused in casual conversations about "thyroid problems," yet they're treated in completely different ways — hyperthyroidism in Graves' disease requires antithyroid drugs, radioactive iodine therapy, or surgery, while hypothyroidism in Hashimoto's is treated with thyroid hormone replacement. This article is not about treating the hyperthyroidism itself in Graves' disease — that's a separate topic requiring an endocrinologist's decision. We focus on a specific, well-studied complication affecting some patients with this disease: Graves' orbitopathy.

Graves' orbitopathy (also called Graves' ophthalmopathy or thyroid eye disease) is an autoimmune inflammatory condition of the tissues of the eye socket — the muscles that move the eyeball, and the fat and connective tissue behind the eye. The same antibodies that overstimulate the thyroid in Graves' disease also attack receptors present in orbital tissues, causing swelling, inflammatory infiltration, and, over the longer term, fibrosis. Clinically this presents as proptosis (bulging of the eyeballs), eyelid swelling, conjunctival redness, a gritty feeling under the eyelids, double vision, and in more severe cases pain and threat to vision from pressure on the optic nerve.

It was in the context of this mild form of the eye disease that the European research group EUGOGO (European Group on Graves' Orbitopathy) conducted a randomized clinical trial testing whether a simple, cheap, and widely available trace element — selenium — could actually help.

Several features of this study make it particularly credible: it's not a small, single-center report, but a multicenter trial conducted in parallel across several European reference centers specializing in Graves' orbitopathy, with double blinding (neither patients nor evaluating physicians knew who received which preparation) and a placebo control group rather than simply no treatment. The effect also persisted after supplementation stopped, suggesting a real influence on the disease course rather than just temporary symptom relief while taking the preparation.

The third arm of this study — pentoxifylline, a drug used among other things for peripheral circulatory disorders, tested here for its potential anti-inflammatory action — showed no significant advantage over placebo on any of the evaluated orbitopathy parameters. Moreover, patients taking pentoxifylline reported gastrointestinal complaints more often than in the other two groups, and one of them required escalation to immunosuppression despite treatment.

This is a rare example of a study that, in a single experiment, provides both strong evidence "for" (selenium) and equally strong evidence "against" (pentoxifylline) — with both answers coming from the same rigorous methodology, the same patient population, and the same team of researchers. That internal consistency makes the results unusually credible compared with separate, independent studies that are harder to compare directly.